

27. Drug resistant TB: outcomes
Saturday, 05 December 2015, 12:30-13:30

Chair: Faiz AHMAD KHAN (Canada)

Track: Drug-resistant TB care and treatment, including trials

- ~~PC-925-05~~ ~~Shortening length of treatment in MDR-TB patients using a six drug anti-tuberculosis regimen~~
CANCELLED
- PC-926-05 **Residual efficacy of levofloxacin versus moxifloxacin against fluoroquinolone-resistant M. tuberculosis murine infection**
T Maitre, A Chauffour, C Bernard, A Aubry, N Veziris (*France*)
- PC-927-05 **Amplification to rifampicin resistance by not addressing isoniazid mono/polyresistance under India's MDR-TB programme**
M Parmar, Ks Sachdeva, S Balakrishnan, A Amar Shah, M Ghedia, F Sayyed Imran, R Ramachandran, A Sreenivas (*India*)
- PC-928-05 **High efficacy of the Peruvian XDR-TB regimen for culture conversion in programmatic conditions**
V Alarcon, D Vargas, J Cabrera, D Vela Trejo, R Espinoza, J Diaz, J Cornejo, A Mendoza, A Valentina Antonieta, A Mendoza-Ticona (*Peru*)
- PC-929-05 **Isoniazid, even at low dose, exerts some anti-tuberculosis activity against isoniazid-resistant Mycobacterium tuberculosis in mice**
R Swanson, N Ammerman, C Moodley, A Dorasamy, A Tapley, J Grosset, C Rodrigues, D Almeida (*USA, India*)
- PC-930-05 **Two-year survival in patients with XDR-TB from two provinces in South Africa**
C Kvasnovsky, M Van Der Walt (*UK, South Africa*)
- PC-931-05 **Polymorphisms in the vitamin D receptor gene reduce the rate of sputum culture conversion in multidrug-resistant tuberculosis patients in South Africa**
M Magee, Y Sun, S Shah, S Allana, J Brust, Q Hui, T Mthiyane, N Gandhi (*USA, South Africa*)